Steven D. Harr, M.D.

Steven D. Harr, M.D.

President, Chief Executive Officer, and DirectoratSana Biotechnology· In proxies 2022–2025

Pay in FY2025-67% from the year before · Sana Biotechnology stock +149.7% the same year

Steven D. Harr, M.D. was paid $2.9M in FY2025 (Dec), down 67%. Sana Biotechnology stock rose 149.7% that year.

Pay$100 in the stock at the end of FY21 → $26
Pay is from the Summary Compensation Table of each Sana Biotechnology proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Sana BiotechnologyPublic company · 4 yr
    • President, Chief Executive Officer, and Director2022 – Present · 4 yrStock in role -83%
  2. LoxoPublic company
    • Director? – PresentNo stock prices for these years
  3. Loxo Oncology, Inc.Public company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?